Form D · Biotechnology
Superluminal Medicines, Inc.
Boston, MA · CIK 0001989478
Offering snapshot reported Sep 3, 2026 · SEC filing
- Reported sold
- $65.5M Offering amount: $65.5M
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 10, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 3, 2026 | Initial | $65,480,796 | No comparison | 16 | SEC filing |
| Aug 26, 2025 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
| Sep 4, 2024 | Initial | $20,041,660 | No comparison | 12 | SEC filing |
| Aug 28, 2023 | Initial | $25,679,107 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-596351
Source: Form D, filed Sep 3, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Cony D'cruz | Director, Executive, Promoter |
| Andrew Levin | Director |
| Dylan Morris | Director |
| Harsha Paladugu | Director |
| Craig Randall | Executive |
| Catherine Riesen | Executive |
| Nandita Shangari | Director |
| Diamantis Xylas | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
15 Necco St. Lilly Gateway Labs, 4 Th Floor
Boston, MA, 02110
Phone: (301) 525-8752
Boston, MA, 02110
Phone: (301) 525-8752